---
pmid: '27038547'
title: MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3.
authors:
- Liu Y
- Liu G
- Zhang H
- Wang J
journal: Biochem Biophys Res Commun
year: '2016'
full_text_available: false
doi: 10.1016/j.bbrc.2016.03.140
---

# MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3.
**Authors:** Liu Y, Liu G, Zhang H, Wang J
**Journal:** Biochem Biophys Res Commun (2016)
**DOI:** [10.1016/j.bbrc.2016.03.140](https://doi.org/10.1016/j.bbrc.2016.03.140)

## Abstract

1. Biochem Biophys Res Commun. 2016 May 13;473(4):859-866. doi: 
10.1016/j.bbrc.2016.03.140. Epub 2016 Mar 30.

MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3.

Liu Y(1), Liu G(2), Zhang H(1), Wang J(3).

Author information:
(1)Department of Respiratory and Critical Care Medicine, First Affiliated 
Hospital of ZhengZhou University, ZhengZhou 450052, China.
(2)Department of Gastrointestinal Surgery, First Affiliated Hospital of 
ZhengZhou University, ZhengZhou 450052, China.
(3)Department of Respiratory and Critical Care Medicine, First Affiliated 
Hospital of ZhengZhou University, ZhengZhou 450052, China. Electronic address: 
jingwangcc@126.com.

MicroRNAs (miRNAs) play important roles in pulmonary artery hypertension (PAH). 
Recently, it has been reported that miR-199a-5p participates in the progression 
of chronic obstructive pulmonary disease, ventricular hypertrophy and heart 
failure. However, the roles of miR-199a-5p in PAH are still unclear. In the 
present study, miR-199a-5p was investigated in PAH rat models and in human 
pulmonary artery smooth muscle cells (HPASMCs) and endothelial cells (HPAECs). 
The expression of miR-199a-5p was significantly increased following PAH 
induction, and anti-miR-199a-5p could increase the nitric oxide (NO) level and 
decrease the PAH-induced upregulation of pulmonary artery pressure and right 
ventricular hypertrophy. Moreover, in HPASMCs and HPAECs, miR-199a-5p 
overexpression could inhibit the level of NO and promote the concentration of 
Ca(2+), but anti-miR-199a-5p showed opposite results. Further analysis 
demonstrated that miR-199a-5p attenuated the expression of Smad3. Importantly, 
Smad3 was confirmed to be the target gene of miR-199a-5p using dual-luciferase 
reporter assay. Mechanism analyses revealed that the downregulation of NO and 
the upregulation of Ca(2+) caused by miR-199a-5p were all reversed by Smad3 
overexpression in HPASMCs and HPAECs. Moreover, in PAH model, Smad3, p-Smad3 and 
Smad4 were all downregulated in lung tissues, and SIS3 (Smad3 inhibitor) could 
reverse the effects of anti-miR-199a-5p in PAH rats. Our date suggest that 
miR-199a-5p may function as a regulator of PAH by targeting Smad3, indicating a 
novel therapeutic strategy for patients with PAH.

Copyright Â© 2016 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.bbrc.2016.03.140
PMID: 27038547 [Indexed for MEDLINE]
